<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02559505</url>
  </required_header>
  <id_info>
    <org_study_id>RSRB00058437</org_study_id>
    <nct_id>NCT02559505</nct_id>
  </id_info>
  <brief_title>Influenza Immunity in Children</brief_title>
  <official_title>Understanding How the Initial Encounter With Influenza Virus Poises Children for Protective Immunity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates how different methods of early exposure to influenza (natural infection,&#xD;
      live attenuated influenza vaccination, inactivated influenza vaccination) initially stimulate&#xD;
      immunity and poise the immune system to respond to a future challenge with the inactivated&#xD;
      influenza vaccine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed research addresses the fact that, despite high childhood morbidity from&#xD;
      influenza and broad recommendations for vaccination, very little is known about how&#xD;
      anti-influenza immunity is shaped by the method of initial exposure. The objective of this&#xD;
      research is to understand how CD4 T cell and B cell responses are altered by the method of&#xD;
      initial influenza priming, with the long-term goal of determining how a child's initial&#xD;
      influenza encounter poises the immune system to respond to subsequent influenza challenges.&#xD;
      The investigators central hypothesis is that differences in the mode of influenza antigen&#xD;
      exposure in early childhood will generate long lasting, detectable changes in memory CD4 T&#xD;
      cell and B cell specificity and function that influence the response to future influenza&#xD;
      vaccinations and infections. This hypothesis will be tested by comparing 1) CD4 T cell and 2)&#xD;
      antibody responses in cohorts of children initially exposed to influenza through either&#xD;
      natural infection or inactivated or live attenuated vaccination. A combination of&#xD;
      multiparameter assays will be used to determine the phenotype and functional potential of&#xD;
      hemagglutinin (HA)- and nucleoprotein (NP)-specific CD4 T cells. The breadth and avidity of&#xD;
      the neutralizing and non-neutralizing antibody responses and its distribution against head&#xD;
      and stalk epitopes will also be evaluated. By determining how initial priming shapes the&#xD;
      specificity and functional potential of the anti-influenza CD4 T cell and antibody responses,&#xD;
      the investigators will gain the knowledge necessary to optimize current influenza vaccination&#xD;
      strategies and develop novel influenza vaccines able to provide highly efficacious universal&#xD;
      protection against both seasonal and potentially pandemic viral strains.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Actual">July 3, 2020</completion_date>
  <primary_completion_date type="Actual">July 3, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percent of IFNg+ CD69+ CD4 T Cells Between Acute (H3N2) Infected and Vaccinated Subjects</measure>
    <time_frame>Visit 2 (day 8-14 post enrollment)</time_frame>
    <description>% H3- and nucleoprotein (NP)-specific CD4 T cells were measured using intracellular cytokine staining</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Percent of IFNg+ CD69+ CD4 T Cells Between Acute (H3N2) Infected and Vaccinated Subjects</measure>
    <time_frame>Visit 3 (day 20-28 post enrollment)</time_frame>
    <description>% H3- and nucleoprotein (NP)-specific CD4 T cells were measured using intracellular cytokine staining</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Percent of IFNg+ CD69+ CD4 T Cells Between Acute (H3N2) Infected and Vaccinated Subjects</measure>
    <time_frame>Visit 4 (day of vaccination year 2)</time_frame>
    <description>% H3- and nucleoprotein (NP)-specific CD4 T cells were measured using intracellular cytokine staining</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Percent of IFNg+ CD69+ CD4 T Cells Between Acute (H3N2) Infected and Vaccinated Subjects</measure>
    <time_frame>Visit 5 (day 8-14 post-vaccination year 2)</time_frame>
    <description>% H3 protein- and nucleoprotein (NP)-specific CD4 T cells were measured using intracellular cytokine staining</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Percent of IFNg+ CD69+ CD4 T Cells Between Acute (H3N2) Infected and Vaccinated Subjects</measure>
    <time_frame>Visit 6 (day 20-28 post-vaccination year 2)</time_frame>
    <description>% H3 Protein- and nucleoprotein (NP)-specific CD4 T cells were measured using intracellular cytokine staining</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Percent of IFNg+ CD69+ CD4 T Cells Between Vaccinated Subjects in Different Age Subsets</measure>
    <time_frame>Baseline to day 24 study year 1</time_frame>
    <description>CD4 T cell quantity and specificity will be measured using intracellular cytokine staining. We report here the mean change in percent of cells reactive to the influenza HA protein and H3 protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Percent of IFNg+ CD69+ CD4 T Cells Between Vaccinated Subjects in Different Age Subsets</measure>
    <time_frame>Baseline to day 24 study year 2</time_frame>
    <description>CD4 T cell quantity and specificity will be measured using intracellular cytokine staining. We report here the mean change in percent of cells reactive to the influenza HA protein and H3 protein.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline to Day 10 and Day 24 in PBMC Gene Expression</measure>
    <time_frame>Days 10 and 24 post vaccination</time_frame>
    <description>Changes in PBMC gene expression patterns due to prior influenza exposure will be assessed using RNA-seq analysis</description>
  </other_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>6-12 months Seasonal IIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children 6 - 12 months of age vaccinated with seasonal IIV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3-12 months natural infection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children 3-12 months of age presenting with natural influenza infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>13-35 months Seasonal IIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children 13-35 months of age vaccinated with seasonal IIV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>13-35 months natural infection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children 13-35 months of age presenting with natural influenza infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3-5 years Seasonal IIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children 3-5 years of age vaccinated with seasonal IIV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3-5 years natural infection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children 3-5 years of age presenting with natural influenza infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6-8 years Seasonal IIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children 6-8 years of age vaccinated with seasonal IIV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6-8 years natural infection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children 6-8 years of age presenting with natural influenza infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Seasonal IIV 0.25 mL dose</intervention_name>
    <description>Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age</description>
    <arm_group_label>13-35 months Seasonal IIV</arm_group_label>
    <arm_group_label>6-12 months Seasonal IIV</arm_group_label>
    <other_name>Inactivated influenza vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Natural influenza infection</intervention_name>
    <description>Children enrolled on presentation to their primary care provider with a natural influenza infection</description>
    <arm_group_label>13-35 months natural infection</arm_group_label>
    <arm_group_label>3-12 months natural infection</arm_group_label>
    <arm_group_label>3-5 years natural infection</arm_group_label>
    <arm_group_label>6-8 years natural infection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Seasonal IIV 0.5 mL dose</intervention_name>
    <description>Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age</description>
    <arm_group_label>13-35 months natural infection</arm_group_label>
    <arm_group_label>3-12 months natural infection</arm_group_label>
    <arm_group_label>3-5 years Seasonal IIV</arm_group_label>
    <arm_group_label>3-5 years natural infection</arm_group_label>
    <arm_group_label>6-8 years Seasonal IIV</arm_group_label>
    <arm_group_label>6-8 years natural infection</arm_group_label>
    <other_name>inactivated influenza vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&#xD;
&#xD;
               -  Between 6 and 12 months to participate in the vaccination arm of cohort 1 (cohort&#xD;
                  1A)&#xD;
&#xD;
               -  Between 3 and 12 months to participate in the natural infection arm of cohort 1&#xD;
                  (cohort 1B)&#xD;
&#xD;
               -  Between 13 and 35 months of age to participate in either the vaccination or&#xD;
                  natural infection arm of cohort 2&#xD;
&#xD;
               -  Between 36 months and 5 years of age to participate in either the vaccination or&#xD;
                  natural infection arm of cohort 3&#xD;
&#xD;
               -  Between 6 years and 8 years of age to participate in either the vaccination or&#xD;
                  natural infection arm of cohort 4&#xD;
&#xD;
          -  Gestational age of â‰¥37 weeks at birth&#xD;
&#xD;
          -  Parent/guardian can provide informed consent&#xD;
&#xD;
          -  Available for the duration of the study&#xD;
&#xD;
          -  History of previous IIV administration ONLY for participation in the vaccination arm&#xD;
             of cohorts 2, 3, or 4&#xD;
&#xD;
          -  Acute illness documented to be due to influenza virus ONLY for participation in the&#xD;
             natural infection arms of cohorts 1-4&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Immunosuppression as a result of an underlying illness or condition (including HIV or&#xD;
             a primary immunodeficiency syndrome)&#xD;
&#xD;
          -  Active neoplastic disease&#xD;
&#xD;
          -  Use of potentially immunosuppressive medications currently or within the past year&#xD;
             (including chemotherapeutic agents) or chronic (&gt;2 weeks) use of oral or inhaled&#xD;
             steroid therapy&#xD;
&#xD;
          -  A diagnosis of asthma requiring chronic controller medication&#xD;
&#xD;
          -  Previous administration of influenza vaccine in the current influenza season ONLY for&#xD;
             subjects receiving an influenza vaccination&#xD;
&#xD;
          -  Receipt of immunoglobulin or another blood product within the year prior to study&#xD;
             enrollment&#xD;
&#xD;
          -  An acute illness within the previous 3 days or temperature &gt;38o on screening EXCEPT&#xD;
             for participation in the natural infection arms of cohorts 1-4&#xD;
&#xD;
          -  A contraindication to influenza vaccination EXCEPT infants between 3 and 5 months&#xD;
             presenting with natural influenza infection whose only contraindication is their&#xD;
             current age&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer L Nayak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 18, 2015</study_first_submitted>
  <study_first_submitted_qc>September 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2015</study_first_posted>
  <results_first_submitted>August 5, 2021</results_first_submitted>
  <results_first_submitted_qc>August 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 2, 2021</results_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Jennifer Nayak</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>natural influenza infection</keyword>
  <keyword>live attenuated influenza vaccination (LAIV)</keyword>
  <keyword>inactivated influenza vaccination (IIV)</keyword>
  <keyword>infants</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 21, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT02559505/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 4, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT02559505/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Acute</title>
          <description>Children enrolled on presentation to their primary care provider with a natural influenza infection.</description>
        </group>
        <group group_id="P2">
          <title>Vaccinated</title>
          <description>Seasonal IIV 0.25 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>6-12 Months of Age: Vaccinated</title>
          <description>Children 6 - 12 months of age vaccinated with seasonal IIV&#xD;
Seasonal IIV 0.25 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age</description>
        </group>
        <group group_id="B2">
          <title>3-12 Months of Age: Acute</title>
          <description>Children 3-12 months of age presenting with natural influenza infection&#xD;
Natural influenza infection: Children enrolled on presentation to their primary care provider with a natural influenza infection&#xD;
Seasonal IIV 0.5 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age</description>
        </group>
        <group group_id="B3">
          <title>13-35 Months of Age: Vaccinated</title>
          <description>Children 13-35 months of age vaccinated with seasonal IIV&#xD;
Seasonal IIV 0.25 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age</description>
        </group>
        <group group_id="B4">
          <title>13-35 Months of Age: Acute</title>
          <description>Children 13-35 months of age presenting with natural influenza infection&#xD;
Natural influenza infection: Children enrolled on presentation to their primary care provider with a natural influenza infection&#xD;
Seasonal IIV 0.5 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age</description>
        </group>
        <group group_id="B5">
          <title>3-5 Years of Age: Vaccinated</title>
          <description>Children 3-5 years of age vaccinated with seasonal IIV&#xD;
Seasonal IIV 0.5 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age</description>
        </group>
        <group group_id="B6">
          <title>3-5 Years of Age: Acute</title>
          <description>Children 3-5 years of age presenting with natural influenza infection&#xD;
Natural influenza infection: Children enrolled on presentation to their primary care provider with a natural influenza infection&#xD;
Seasonal IIV 0.5 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age</description>
        </group>
        <group group_id="B7">
          <title>6-8 Years of Age: Vaccinated</title>
          <description>Children 6-8 years of age vaccinated with seasonal IIV&#xD;
Seasonal IIV 0.5 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age</description>
        </group>
        <group group_id="B8">
          <title>6-8 Years of Age: Acute</title>
          <description>Children 6-8 years of age presenting with natural influenza infection&#xD;
Natural influenza infection: Children enrolled on presentation to their primary care provider with a natural influenza infection&#xD;
Seasonal IIV 0.5 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="19"/>
            <count group_id="B5" value="18"/>
            <count group_id="B6" value="12"/>
            <count group_id="B7" value="23"/>
            <count group_id="B8" value="9"/>
            <count group_id="B9" value="132"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="23"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="13"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="23"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="23"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent of IFNg+ CD69+ CD4 T Cells Between Acute (H3N2) Infected and Vaccinated Subjects</title>
        <description>% H3- and nucleoprotein (NP)-specific CD4 T cells were measured using intracellular cytokine staining</description>
        <time_frame>Visit 2 (day 8-14 post enrollment)</time_frame>
        <population>6 acute participants were infected with influenza strains that were not H3 and therefore were not included in the data analyzed for the primary outcome. Only vaccinated participants that age matched to the acute subjects were analyzed, resulting in 16 acutely infected and 28 vaccinated subjects included in the data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Acute Infected</title>
            <description>Children enrolled on presentation to their primary care provider with a natural influenza infection</description>
          </group>
          <group group_id="O2">
            <title>Vaccinated</title>
            <description>Seasonal IIV 0.25 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent of IFNg+ CD69+ CD4 T Cells Between Acute (H3N2) Infected and Vaccinated Subjects</title>
          <description>% H3- and nucleoprotein (NP)-specific CD4 T cells were measured using intracellular cytokine staining</description>
          <population>6 acute participants were infected with influenza strains that were not H3 and therefore were not included in the data analyzed for the primary outcome. Only vaccinated participants that age matched to the acute subjects were analyzed, resulting in 16 acutely infected and 28 vaccinated subjects included in the data analysis.</population>
          <units>percentage of T cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nucleoprotein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".010" spread="0.0023"/>
                    <measurement group_id="O2" value="0.003" spread="0.0018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3 protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.009" spread="0.0019"/>
                    <measurement group_id="O2" value="0.002" spread="0.0015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>p-value for H3 reactivity, difference of Acute Infected vs. Vaccinated.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.024</p_value>
            <p_value_desc>p-value for NP reactivity, difference of Acute Infected vs. Vaccinated.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent of IFNg+ CD69+ CD4 T Cells Between Acute (H3N2) Infected and Vaccinated Subjects</title>
        <description>% H3- and nucleoprotein (NP)-specific CD4 T cells were measured using intracellular cytokine staining</description>
        <time_frame>Visit 3 (day 20-28 post enrollment)</time_frame>
        <population>6 acute participants were infected with influenza strains that were not H3 and therefore were not included in the data analyzed for the primary outcome. Only vaccinated participants that age matched to the acute subjects were analyzed, resulting in 16 acutely infected and 28 vaccinated subjects included in the data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Acute Infected</title>
            <description>Children enrolled on presentation to their primary care provider with a natural influenza infection.</description>
          </group>
          <group group_id="O2">
            <title>Vaccinated</title>
            <description>Seasonal IIV 0.25 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent of IFNg+ CD69+ CD4 T Cells Between Acute (H3N2) Infected and Vaccinated Subjects</title>
          <description>% H3- and nucleoprotein (NP)-specific CD4 T cells were measured using intracellular cytokine staining</description>
          <population>6 acute participants were infected with influenza strains that were not H3 and therefore were not included in the data analyzed for the primary outcome. Only vaccinated participants that age matched to the acute subjects were analyzed, resulting in 16 acutely infected and 28 vaccinated subjects included in the data analysis.</population>
          <units>Percentage of T cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nucleoprotein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.012" spread="0.0025"/>
                    <measurement group_id="O2" value="0.003" spread="0.0017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3 Protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.006" spread="0.0021"/>
                    <measurement group_id="O2" value="0.004" spread="0.0014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.408</p_value>
            <p_value_desc>p-value for H3 reactivity, difference of Acute Infected vs. Vaccinated.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>p-value for NP reactivity, difference of Acute Infected vs. Vaccinated.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent of IFNg+ CD69+ CD4 T Cells Between Acute (H3N2) Infected and Vaccinated Subjects</title>
        <description>% H3- and nucleoprotein (NP)-specific CD4 T cells were measured using intracellular cytokine staining</description>
        <time_frame>Visit 4 (day of vaccination year 2)</time_frame>
        <population>6 acute participants were infected with influenza strains that were not H3 and therefore were not included in the data analyzed for the primary outcome. Only vaccinated participants that age matched to the acute subjects were analyzed, resulting in 16 acutely infected and 28 vaccinated subjects included in the data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Acute Infected</title>
            <description>Children enrolled on presentation to their primary care provider with a natural influenza infection</description>
          </group>
          <group group_id="O2">
            <title>Vaccinated</title>
            <description>Seasonal IIV 0.25 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent of IFNg+ CD69+ CD4 T Cells Between Acute (H3N2) Infected and Vaccinated Subjects</title>
          <description>% H3- and nucleoprotein (NP)-specific CD4 T cells were measured using intracellular cytokine staining</description>
          <population>6 acute participants were infected with influenza strains that were not H3 and therefore were not included in the data analyzed for the primary outcome. Only vaccinated participants that age matched to the acute subjects were analyzed, resulting in 16 acutely infected and 28 vaccinated subjects included in the data analysis.</population>
          <units>Percentage of T cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nucleoprotein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003" spread="0.0030"/>
                    <measurement group_id="O2" value="0.003" spread="0.0018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3 Protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.007" spread="0.0022"/>
                    <measurement group_id="O2" value="0.003" spread="0.0015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.991</p_value>
            <p_value_desc>p-value for H3 reactivity, difference of Acute Infected vs. Vaccinated.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.334</p_value>
            <p_value_desc>p-value for NP reactivity, difference of Acute Infected vs. Vaccinated.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent of IFNg+ CD69+ CD4 T Cells Between Acute (H3N2) Infected and Vaccinated Subjects</title>
        <description>% H3 protein- and nucleoprotein (NP)-specific CD4 T cells were measured using intracellular cytokine staining</description>
        <time_frame>Visit 5 (day 8-14 post-vaccination year 2)</time_frame>
        <population>6 acute participants were infected with influenza strains that were not H3 and therefore were not included in the data analyzed for the primary outcome. Only vaccinated participants that age matched to the acute subjects were analyzed, resulting in 16 acutely infected and 28 vaccinated subjects included in the data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Acute Infected</title>
            <description>Children enrolled on presentation to their primary care provider with a natural influenza infection</description>
          </group>
          <group group_id="O2">
            <title>Vaccinated</title>
            <description>Seasonal IIV 0.25 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent of IFNg+ CD69+ CD4 T Cells Between Acute (H3N2) Infected and Vaccinated Subjects</title>
          <description>% H3 protein- and nucleoprotein (NP)-specific CD4 T cells were measured using intracellular cytokine staining</description>
          <population>6 acute participants were infected with influenza strains that were not H3 and therefore were not included in the data analyzed for the primary outcome. Only vaccinated participants that age matched to the acute subjects were analyzed, resulting in 16 acutely infected and 28 vaccinated subjects included in the data analysis.</population>
          <units>Percentage of T cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nucleoprotein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.010" spread="0.0031"/>
                    <measurement group_id="O2" value="0.003" spread="0.0018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3 Protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.008" spread="0.0026"/>
                    <measurement group_id="O2" value="0.004" spread="0.0015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.226</p_value>
            <p_value_desc>p-value for H3 reactivity, difference of Acute Infected vs. Vaccinated.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.036</p_value>
            <p_value_desc>p-value for NP reactivity, difference of Acute Infected vs. Vaccinated.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent of IFNg+ CD69+ CD4 T Cells Between Acute (H3N2) Infected and Vaccinated Subjects</title>
        <description>% H3 Protein- and nucleoprotein (NP)-specific CD4 T cells were measured using intracellular cytokine staining</description>
        <time_frame>Visit 6 (day 20-28 post-vaccination year 2)</time_frame>
        <population>6 acute participants were infected with influenza strains that were not H3 and therefore were not included in the data analyzed for the primary outcome. Only vaccinated participants that age matched to the acute subjects were analyzed, resulting in 16 acutely infected and 28 vaccinated subjects included in the data analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Acute Infected</title>
            <description>Children enrolled on presentation to their primary care provider with a natural influenza infection.</description>
          </group>
          <group group_id="O2">
            <title>Vaccinated</title>
            <description>Seasonal IIV 0.25 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent of IFNg+ CD69+ CD4 T Cells Between Acute (H3N2) Infected and Vaccinated Subjects</title>
          <description>% H3 Protein- and nucleoprotein (NP)-specific CD4 T cells were measured using intracellular cytokine staining</description>
          <population>6 acute participants were infected with influenza strains that were not H3 and therefore were not included in the data analyzed for the primary outcome. Only vaccinated participants that age matched to the acute subjects were analyzed, resulting in 16 acutely infected and 28 vaccinated subjects included in the data analysis.</population>
          <units>Percentage of T cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nucleoprotein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.014" spread="0.0029"/>
                    <measurement group_id="O2" value="0.003" spread="0.0019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3 Protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.008" spread="0.0024"/>
                    <measurement group_id="O2" value="0.007" spread="0.0015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.680</p_value>
            <p_value_desc>p-value for H3 reactivity, difference of Acute Infected vs. Vaccinated.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>p-value for H3 reactivity, difference of Acute Infected vs. Vaccinated.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Percent of IFNg+ CD69+ CD4 T Cells Between Vaccinated Subjects in Different Age Subsets</title>
        <description>CD4 T cell quantity and specificity will be measured using intracellular cytokine staining. We report here the mean change in percent of cells reactive to the influenza HA protein and H3 protein.</description>
        <time_frame>Baseline to day 24 study year 1</time_frame>
        <population>Statistical analysis was completed on all patients who attended all six clinical visits in addition to those who had 3 or more visits that had withdrawn later.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccinated Age Subset (6-12 mo)</title>
            <description>Seasonal IIV 0.25 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 - 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Vaccinated Age Subset (13-35 mo)</title>
            <description>Seasonal IIV 0.25 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 13 - 35 months.</description>
          </group>
          <group group_id="O3">
            <title>Vaccinated Age Subset (3-5 yr)</title>
            <description>Seasonal IIV 0.25 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 3 - 5 years.</description>
          </group>
          <group group_id="O4">
            <title>Vaccinated Age Subset (6-8 yr)</title>
            <description>Seasonal IIV 0.25 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 - 8 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Percent of IFNg+ CD69+ CD4 T Cells Between Vaccinated Subjects in Different Age Subsets</title>
          <description>CD4 T cell quantity and specificity will be measured using intracellular cytokine staining. We report here the mean change in percent of cells reactive to the influenza HA protein and H3 protein.</description>
          <population>Statistical analysis was completed on all patients who attended all six clinical visits in addition to those who had 3 or more visits that had withdrawn later.</population>
          <units>Mean Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00112" spread="0.00290"/>
                    <measurement group_id="O2" value="0.00497" spread="0.00966"/>
                    <measurement group_id="O3" value="0.00622" spread="0.01098"/>
                    <measurement group_id="O4" value="0.01713" spread="0.02657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0006729" spread="0.0017802"/>
                    <measurement group_id="O2" value="0.0002589" spread="0.005017"/>
                    <measurement group_id="O3" value="0.0053456" spread="0.0101449"/>
                    <measurement group_id="O4" value="0.001674" spread="0.008319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Percent of IFNg+ CD69+ CD4 T Cells Between Vaccinated Subjects in Different Age Subsets</title>
        <description>CD4 T cell quantity and specificity will be measured using intracellular cytokine staining. We report here the mean change in percent of cells reactive to the influenza HA protein and H3 protein.</description>
        <time_frame>Baseline to day 24 study year 2</time_frame>
        <population>Statistical analysis was completed on all patients who attended all six clinical visits in addition to those who had 3 or more visits that had withdrawn later.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccinated Age Subset (6-12 mo)</title>
            <description>Seasonal IIV 0.25 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 - 12 months.</description>
          </group>
          <group group_id="O2">
            <title>Vaccinated Age Subset (13-35 mo)</title>
            <description>Seasonal IIV 0.25 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 13 - 35 months.</description>
          </group>
          <group group_id="O3">
            <title>Vaccinated Age Subset (3-5 yr)</title>
            <description>Seasonal IIV 0.25 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 3 - 5 years.</description>
          </group>
          <group group_id="O4">
            <title>Vaccinated Age Subset (6-8 yr)</title>
            <description>Seasonal IIV 0.25 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 - 8 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Percent of IFNg+ CD69+ CD4 T Cells Between Vaccinated Subjects in Different Age Subsets</title>
          <description>CD4 T cell quantity and specificity will be measured using intracellular cytokine staining. We report here the mean change in percent of cells reactive to the influenza HA protein and H3 protein.</description>
          <population>Statistical analysis was completed on all patients who attended all six clinical visits in addition to those who had 3 or more visits that had withdrawn later.</population>
          <units>Mean Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00552" spread="0.01436"/>
                    <measurement group_id="O2" value="0.00331" spread="0.01216"/>
                    <measurement group_id="O3" value="0.00003" spread="0.01096"/>
                    <measurement group_id="O4" value="0.005698" spread="0.01729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00350" spread="0.00372"/>
                    <measurement group_id="O2" value="0.00177" spread="0.00371"/>
                    <measurement group_id="O3" value="0.00188" spread="0.00650"/>
                    <measurement group_id="O4" value="-0.0017093" spread="0.01015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline to Day 10 and Day 24 in PBMC Gene Expression</title>
        <description>Changes in PBMC gene expression patterns due to prior influenza exposure will be assessed using RNA-seq analysis</description>
        <time_frame>Days 10 and 24 post vaccination</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 18 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>6-12 Months: Vaccinated</title>
          <description>Children 6 - 12 months of age vaccinated with seasonal IIV&#xD;
Seasonal IIV 0.25 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age</description>
        </group>
        <group group_id="E2">
          <title>3-12 Months: Acute</title>
          <description>Children 3-12 months of age presenting with natural influenza infection&#xD;
Natural influenza infection: Children enrolled on presentation to their primary care provider with a natural influenza infection&#xD;
Seasonal IIV 0.5 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age</description>
        </group>
        <group group_id="E3">
          <title>13-35 Months: Vaccinated</title>
          <description>Children 13-35 months of age vaccinated with seasonal IIV&#xD;
Seasonal IIV 0.25 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age</description>
        </group>
        <group group_id="E4">
          <title>13-35 Months: Acute</title>
          <description>Children 13-35 months of age presenting with natural influenza infection&#xD;
Natural influenza infection: Children enrolled on presentation to their primary care provider with a natural influenza infection&#xD;
Seasonal IIV 0.5 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age</description>
        </group>
        <group group_id="E5">
          <title>3-5 Years: Vaccinated</title>
          <description>Children 3-5 years of age vaccinated with seasonal IIV&#xD;
Seasonal IIV 0.5 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age</description>
        </group>
        <group group_id="E6">
          <title>3-5 Years: Acute</title>
          <description>Children 3-5 years of age presenting with natural influenza infection&#xD;
Natural influenza infection: Children enrolled on presentation to their primary care provider with a natural influenza infection&#xD;
Seasonal IIV 0.5 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age</description>
        </group>
        <group group_id="E7">
          <title>6-8 Years: Vaccinated</title>
          <description>Children 6-8 years of age vaccinated with seasonal IIV&#xD;
Seasonal IIV 0.5 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age</description>
        </group>
        <group group_id="E8">
          <title>6-8 Years: Acute</title>
          <description>Children 6-8 years of age presenting with natural influenza infection&#xD;
Natural influenza infection: Children enrolled on presentation to their primary care provider with a natural influenza infection&#xD;
Seasonal IIV 0.5 mL dose: Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jennifer Nayak</name_or_title>
      <organization>University Of Rochester</organization>
      <phone>5852767404</phone>
      <email>Jennifer_Nayak@URMC.Rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

